APM
Avidity Partners Management Portfolio holdings
AUM
$499M
This Quarter Return
+16.93%
1 Year Return
+3.47%
3 Year Return
+181.12%
5 Year Return
+409%
10 Year Return
–
AUM
$4.6B
AUM Growth
+$4.6B
(+5.5%)
Cap. Flow
+$336M
Cap. Flow
% of AUM
7.3%
Top 10 Holdings %
Top 10 Hldgs %
38.55%
Holding
111
New
28
Increased
28
Reduced
21
Closed
14
Top Buys
| 1 |
Eli Lilly
LLY
|
$128M |
| 2 |
Prothena Corp
PRTA
|
$119M |
| 3 |
Akero Therapeutics
AKRO
|
$106M |
| 4 |
Sarepta Therapeutics
SRPT
|
$105M |
| 5 |
Axsome Therapeutics
AXSM
|
$68.7M |
Top Sells
| 1 |
AstraZeneca
AZN
|
$161M |
| 2 |
Johnson & Johnson
JNJ
|
$160M |
| 3 |
McKesson
MCK
|
$127M |
| 4 |
UnitedHealth
UNH
|
$124M |
| 5 |
AbbVie
ABBV
|
$116M |
Sector Composition
| 1 | Healthcare | 96.68% |
| 2 | Financials | 0.52% |
| 3 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Eli Lilly
LLY
$657B
| $326M | 6.62% | 1,007,000 +397,000 | +65% | +$128M |
|
2
United Therapeutics
UTHR
$13.8B
| $203M | 4.13% | 970,200 +244,600 | +34% | +$51.2M |
|
3
Neurocrine Biosciences
NBIX
$13.8B
| $197M | 4.01% | 1,855,700 +388,100 | +26% | +$41.2M |
|
4
Arvinas
ARVN
$568M
| $193M | 3.93% | 4,343,500 +987,877 | +29% | +$44M |
|
5
argenx
ARGX
$43.6B
| $174M | 3.53% | 491,800 -80,700 | -14% | -$28.5M |
|
6
Biogen
BIIB
$19.4B
| $160M | 3.26% | 600,000 +159,434 | +36% | +$42.6M |
|
7
Vertex Pharmaceuticals
VRTX
$100B
| $148M | 3.02% | 512,800 -280,200 | -35% | -$81.1M |
|
8
Syndax Pharmaceuticals
SNDX
$1.41B
| $134M | 2.73% | 5,586,900 +136,900 | +3% | +$3.29M |
|
|
9
Prothena Corp
PRTA
$441M
| $119M | 2.42% | +1,967,000 | New | +$119M |
|
10
SPDR S&P Biotech ETF
XBI
$5.07B
| $117M | 2.39% | 1,480,000 -395,000 | -21% | -$31.3M |
|
11
Acadia Healthcare
ACHC
$2.12B
| $109M | 2.21% | 1,389,200 +354,200 | +34% | +$27.7M |
|
|
12
Akero Therapeutics
AKRO
$3.74B
| $106M | 2.16% | +3,122,000 | New | +$106M |
|
|
13
Sarepta Therapeutics
SRPT
$1.78B
| $105M | 2.13% | +948,200 | New | +$105M |
|
14
Humana
HUM
$36.5B
| $103M | 2.09% | 212,000 -200,300 | -49% | -$97.2M |
|
15
Boston Scientific
BSX
$156B
| $98.3M | 2% | 2,538,600 +13,600 | +0.5% | +$527K |
|
16
Immunocore
IMCR
$1.62B
| $97.6M | 1.98% | 2,079,100 +729,100 | +54% | +$34.2M |
|
|
KRTX
17
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $97.1M | 1.97% | 431,800 +227,230 | +111% | +$51.1M |
|
18
Elevance Health
ELV
$71.8B
| $94.3M | 1.92% | 207,600 -233,400 | -53% | -$106M |
|
|
HZNP
19
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $91.7M | 1.87% | 1,482,200 -374,700 | -20% | -$23.2M |
|
20
Zentalis Pharmaceuticals
ZNTL
$122M
| $91.5M | 1.86% | 4,223,100 +637,219 | +18% | +$13.8M |
|
21
Avantor
AVTR
$9.18B
| $88.6M | 1.8% | 4,522,600 -2,130,100 | -32% | -$41.7M |
|
22
Ultragenyx Pharmaceutical
RARE
$2.89B
| $85M | 1.73% | 2,051,600 +572,100 | +39% | +$23.7M |
|
23
Natera
NTRA
$23.1B
| $76M | 1.55% | 1,735,000 +365,900 | +27% | +$16M |
|
|
24
Axsome Therapeutics
AXSM
$6.05B
| $68.7M | 1.4% | +1,538,600 | New | +$68.7M |
|
|
CTLT
25
DELISTED
CATALENT, INC.
CTLT
| $68M | 1.38% | 940,000 -15,000 | -2% | -$1.09M |
|